Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding

Ratios

Kiniksa Pharmaceuticals International (KNSA) Shares Issued (2018 - 2026)

Kiniksa Pharmaceuticals International filings provide 6 years of Shares Issued readings, the most recent being $6.4 million for Q1 2026.

On a quarterly basis, Shares Issued rose 100.91% to $6.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $44.0 million, a 167.47% increase, with the full-year FY2025 number at $40.8 million, up 136.25% from a year prior.
Shares Issued hit $6.4 million in Q1 2026 for Kiniksa Pharmaceuticals International, down from $8.6 million in the prior quarter.
In the past five years, Shares Issued ranged from a high of $16.3 million in Q3 2025 to a low of $510000.0 in Q1 2023.
Median Shares Issued over the past 5 years was $1.7 million (2023), compared with a mean of $4.2 million.
Biggest five-year swings in Shares Issued: tumbled 78.77% in 2022 and later surged 1022.91% in 2025.
Kiniksa Pharmaceuticals International's Shares Issued stood at $1.3 million in 2022, then decreased by 25.81% to $957000.0 in 2023, then skyrocketed by 184.22% to $2.7 million in 2024, then skyrocketed by 215.29% to $8.6 million in 2025, then dropped by 25.5% to $6.4 million in 2026.
The last three reported values for Shares Issued were $6.4 million (Q1 2026), $8.6 million (Q4 2025), and $16.3 million (Q3 2025) per Business Quant data.